Caring Deeply. Changing Lives

We measure success by our impact on patients we serve

Neurotrope BioScience (OTCQB:NTRP), formed in 2012, is at the forefront of the biotech industry and is focused on developing new therapies with Bryostatin 1 for the treatment of neurodegenerative diseases and developmental disorders.


Our experience, capabilities, and passion for innovative and novel drug therapies have enabled us to build a development pipeline that includes various treatment approaches with Bryostatin 1 for serious and difficult-to-treat diseases such as Alzheimer’s dementia and the Orphan diseases, Fragile X Syndrome (FXS) and Niemann-Pick Type C (NPC).


Looking toward the future, Neurotrope BioScience has teamed up with Stanford University to identify the next generation Bryostatin 1 from a group of synthetic compounds called y Bryologs, designed after the naturally-occurring Bryostatin.


Sachs Conference Company Presentation Video

Click here to View

Dr. Dan Alkon Keynote Speech February 2016

Click here to View

April 12, 2016 Annual Meeting Documents

Click here to View

Alzeimer’s disease and Neurodegeneration Presentation

Click here to view

Improving the lives of patients with Alzheimer’s Disease
and other disorders

Click here to view